Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on May 12, 2023. The filing serves to announce the company's financial results for the quarter ended March 31, 2023. AgeX is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California. Its common stock trades on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1 to this report. Consequently, no specific financial metrics can be extracted from the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body text. It references the press release (Exhibit 99.1) for the announcement of results, implying that any material changes are disclosed therein.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: The company directs investors to its periodic reports filed with the SEC under the heading "Risk Factors" for additional factors that could cause actual results to differ materially from anticipated results.
- Outlook: No specific guidance or outlook is provided in the text of this 8-K; it defers to the referenced press release for operational updates.
Important Facts for Investor Verification
- Verify the specific financial figures (revenue, net loss, cash position) in the press release (Exhibit 99.1) referenced in this filing, as they are not listed in the 8-K text.
- Confirm the company name is AgeX Therapeutics, Inc., as the input metadata incorrectly identified it as Serina Therapeutics, Inc.
- Note that the information in Item 2.02 and the press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Review the company's most recent periodic reports for the full list of Risk Factors affecting forward-looking statements.